潰瘍性結腸炎市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測

Ulcerative Colitis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年01月14日 | 出版商:

Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球潰瘍性結腸炎市場規模達到 80 億美元，並將穩定擴張，預計 2025 年至 2034 年的複合年成長率為 5.6%。這一成長主要得益於潰瘍性結腸炎發病率的不斷上升，而城市化、飲食習慣的改變和環境變化導致潰瘍性結腸炎發病率持續上升。隨著越來越多的人接受西方化的生活方式，不良飲食、壓力和污染等因素導致發炎性腸道疾病（IBD）（包括潰瘍性結腸炎）的發生率上升。全球有數百萬人受到影響，對有效和長期治療方案的需求正在增加。

醫學研究的進步促進了新療法的開發，從而提供了更好的疾病管理和改善患者預後。製藥公司正在積極投資新的藥物配方，包括生物製劑和JAK抑制劑，以提供更有針對性的治療。此外，醫療保健系統更加重視早期診斷和干涉，從而提高患者意識並及時提供醫療護理。對以患者為中心的治療方案（包括個人化醫療和聯合療法）的日益關注也在推動市場創新。新藥的監管批准和現有藥物適應症的擴大進一步促進了市場成長，為藥品製造商和醫療保健提供者創造了有利可圖的機會。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	80億美元
預測值	135億美元
複合年成長率	5.6%

根據藥物類型，市場分為氨基水楊酸鹽、生物製劑、皮質類固醇、Janus 激酶 (JAK) 抑制劑、免疫抑制劑等。 2024 年，氨基水楊酸鹽部門的收入為 28 億美元，反映了其廣泛用於治療輕度至中度潰瘍性結腸炎的第一線治療。這些抗發炎藥物在減輕症狀和維持緩解方面非常有效，因此成為許多患者的首選。它們能夠提供長期緩解且沒有顯著副作用，這使得它們在市場上佔據強大的地位。隨著輕症確診率的上升，氨基水楊酸鹽的需求依然旺盛，確保了其在市場上繼續佔據主導地位。

給藥方法在患者偏好和治療依從性方面起著至關重要的作用。市場分為口服和注射療法，其中口服藥物在 2024 年佔 52.2% 的佔有率。許多常用的治療藥物，包括氨基水楊酸鹽、JAK 抑制劑和免疫抑制劑，都有口服劑型，這對患者來說是一種方便的選擇。由於口服藥物易於自行給藥、成本效益高以及減少頻繁就醫的需要，因此成為首選。製藥公司不斷改進藥物輸送系統，提高口服治療的生物利用度和療效，進一步鞏固該領域在市場上的地位。

2024 年美國潰瘍性結腸炎市場價值為 30 億美元，成為全球市場成長最大的區域貢獻者之一。美國潰瘍性結腸炎發生率高，對先進治療方案的需求龐大。完善的醫療保健基礎設施、增加的研發資金以及積極主動的疾病意識方法加速了市場擴張。

The Global Ulcerative Colitis Market reached USD 8 billion in 2024 and is set to experience steady expansion, with a projected CAGR of 5.6% from 2025 to 2034. This growth is largely fueled by the increasing prevalence of ulcerative colitis, which continues to rise due to urbanization, evolving dietary habits, and environmental changes. As more people adopt Westernized lifestyles, factors such as poor diet, stress, and pollution have contributed to a higher incidence of inflammatory bowel diseases (IBD), including ulcerative colitis. With millions affected worldwide, the demand for effective and long-term treatment solutions is on the rise.

Advancements in medical research have led to the development of novel therapies that offer better disease management and improved patient outcomes. Pharmaceutical companies are actively investing in new drug formulations, including biologics and JAK inhibitors, to provide more targeted treatments. Additionally, healthcare systems are placing greater emphasis on early diagnosis and intervention, leading to increased patient awareness and timely medical care. The growing focus on patient-centric treatment plans, including personalized medicine and combination therapies, is also driving innovation within the market. Regulatory approvals for new drugs and expanded indications for existing medications are further contributing to market growth, creating lucrative opportunities for drug manufacturers and healthcare providers.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$8 Billion
Forecast Value	$13.5 Billion
CAGR	5.6%

The market is categorized by drug type into aminosalicylates, biologics, corticosteroids, Janus kinase (JAK) inhibitors, immunosuppressants, and others. In 2024, the aminosalicylates segment generated USD 2.8 billion, reflecting its widespread use as a first-line treatment for mild to moderate ulcerative colitis. These anti-inflammatory drugs are highly effective in reducing symptoms and maintaining remission, making them a preferred option for many patients. Their ability to provide long-term relief without significant side effects has contributed to their strong market presence. With the increasing diagnosis rate of mild cases, the demand for aminosalicylates remains robust, ensuring their continued dominance in the market.

The method of administration plays a critical role in patient preference and treatment compliance. The market is segmented into oral and injectable therapies, with oral medications capturing a 52.2% share in 2024. Many commonly prescribed treatments, including aminosalicylates, JAK inhibitors, and immunosuppressants, are available in oral formulations, making them a convenient option for patients. The ease of self-administration, cost-effectiveness, and reduced need for frequent medical visits make oral drugs the preferred choice. Pharmaceutical companies continue to refine drug delivery systems, enhancing the bioavailability and efficacy of oral treatments, further strengthening this segment's position in the market.

The United States ulcerative colitis market was valued at USD 3 billion in 2024, making it one of the largest regional contributors to global market growth. The high prevalence of ulcerative colitis in the U.S. has driven significant demand for advanced treatment options. A well-established healthcare infrastructure, increased funding for research and development, and a proactive approach to disease awareness have accelerated market expansion.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of ulcerative colitis
  - 3.2.1.2 Expanding treatment options
  - 3.2.1.3 Increasing awareness and diagnosis
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High treatment costs
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Aminosalicylates
5.3 Biologics
5.4 Corticosteroids
5.5 Janus kinase (JAK) inhibitors
5.6 Immunosuppressants
5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Proctosigmoiditis
6.3 Ulcerative proctitis
6.4 Left-sided colitis
6.5 Pancolitis or universal colitis
6.6 Fulminant colitis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE